ILMN Earnings Date: Feb 4, 2027 (Estimated) — Illumina, Inc.
NASDAQ · Healthcare · Diagnostics & Research
Updated
When is ILMN's next earnings date?
Illumina, Inc. (ILMN) is expected to report Q4 2026 earnings on Thursday, February 4, 2027 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $1.53 on revenue of $1.22B.
How did ILMN do in its last earnings report?
In its most recent report on Oct 29, 2026 (Q3 2026), Illumina, Inc. posted EPS of $1.62 versus the $1.36 estimate, a beat of 19.1%. Revenue was $1.17B against a $1.15B estimate.
How much does ILMN stock move after earnings?
ILMN beat EPS estimates in 8 of its last 8 reported quarters. Over the last 7 reports the stock moved an average of 8.7% (up or down) in the day after earnings.
About Illumina, Inc.
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
🤖 AI Earnings Analysis
Illumina’s Q3 was strong: EPS of $1.62 beat estimates by $0.26 as revenue rose to $1.2B from $1.1B, despite distorted reported growth figures. Full-year guidance remains $5.30–$5.40 EPS and $4.6B revenue.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-29 | Q3 2026 | 1.36 | 1.62 | +19.12% | $1.17B | ✅ Beat | — | — | — |
| 2026-07-30 | Q2 2026 | 1.23 | 1.31 | +6.50% | $1.16B | ✅ Beat | +0.00% | -5.54% | +5.12% |
| 2026-04-30 | Q1 2026 | 1.05 | 1.15 | +9.52% | $1.09B | ✅ Beat | +7.13% | +9.44% | +29.71% |
| 2026-02-05 | Q4 2025 | 1.25 | 1.35 | +8.00% | $1.16B | ✅ Beat | -10.40% | -14.35% | -6.98% |
| 2025-10-30 | Q3 2025 | 1.16 | 1.34 | +15.52% | $1.08B | ✅ Beat | +24.78% | +22.32% | +30.01% |
| 2025-07-31 | Q2 2025 | 1.01 | 1.19 | +17.82% | $1.06B | ✅ Beat | -7.84% | -7.02% | -2.68% |
| 2025-02-06 | Q4 2024 | 0.92 | 0.95 | +3.26% | $1.10B | ✅ Beat | -9.56% | -17.12% | -29.99% |
| 2024-11-04 | Q3 2024 | 0.88 | 1.14 | +29.55% | $1.08B | ✅ Beat | +0.96% | -1.30% | -7.16% |
Showing last 8 quarters.